Pharmaceutical Technologist - November 2007 - (Page 12)

Feeling the pressure Murray Aitken of IMS Health gives global pharma a ‘check-up’ after a tumultuous year of market shifts and product shake-ups. In ways both expected and unexpected, 2006 was a year of tumult for global pharma as the dynamics of the market continued to shift. New products shook up major therapy classes, promising molecules stumbled, governments and others tackled issues of access and affordability in earnest, and at least one major group (the Gates Foundation) threatened to side-step the pharma industry in seeking new solutions for HIV/AIDS. At the same time, millions of patients were newly diagnosed, treated and helped by pharmacotherapy. (€446.14 billion), reflecting increased longevity of populations, strong economies and innovative new products (Figure 1). In particular, a rebound in US growth to 8.3% (led by an increase in prescribing volume as a result of Medicare Part D) and innovations in oncologics, which drove 20.5% global growth in that therapy area, were key contributors to this performance. The US continued to account for about half of total growth but, in a significant rebalancing of markets, 27% of growth came from countries with a per capita Gross National Income of less than $20000 (€13880). As recently as 2001, these lower-income countries contributed just 13%. Western Europe drove only 16% of growth — compared with 29% 5 years previously. IMS believes the relative contribution to future growth will continue to skew away from the US and five major European markets. A changing balance in growth contribution was also apparent in the product arena, with specialist-driven products contributing approximately 62% compared with just 35% in 2000 (Figure 2). There continues to be a shift away from mature markets to emerging ones, and from primary care classes to biotech and specialist-driven therapies, which are experiencing double-digit growth in major markets. Oncology and autoimmune products increasingly are demonstrating their value in answering unmet patient needs — Market rebalancing The size of the total market expanded as anticipated in 2006, growing by 7% to $643 billion 12 November 2007 l pharmaceutical technologist

Table of Contents Feed for the Digital Edition of Pharmaceutical Technologist - November 2007

Pharmaceutical Technologist Contents Editor's Comment News Morpheus Feeling the Pressure Legal Crusaders The Holy-Grail of Start-Up Biotech Special Feature Q&A

Pharmaceutical Technologist - November 2007

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.